ENTPD1 and neoplasm: A better understanding of the mechanisms underlying the beneficial and adverse effects of purinergic signaling in tumor and normal tissue responses to RT will allow us to define rational strategies for exploiting the CD39/CD73 immune checkpoint to improve RT outcome.